- Q1 2024 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024€201.3 (-7.53%)Earnings
- Madrigal Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Madrigal Pharmaceuticals Inc at UBS BioPharma Conference TranscriptNov 08, 2023
- Madrigal Pharmaceuticals Inc Phase 3 MAESTRO-NASH Trial Investor Call TranscriptJun 24, 2023
- Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Madrigal Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptMay 16, 2023
- Madrigal Pharmaceuticals Inc to Announce Topline Data from the Phase 3 MAESTRO-NASH Study of Resmetirom Presentation TranscriptDec 19, 2022
- Madrigal Pharmaceuticals Inc EASL Investor Event Call TranscriptJun 25, 2022
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference TranscriptMay 24, 2022
- Q1 2022 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2022€54.5 (-10.66%)Earnings
- Madrigal Pharmaceuticals Inc Call to Discuss MAESTRO-NAFLD-1 Phase 3 Data TranscriptJan 31, 2022
- Madrigal Pharmaceuticals Inc AASLD The Liver Meeting Call TranscriptNov 16, 2021
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference TranscriptMay 24, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 19, 2020
Madrigal Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Good afternoon. I actually had to check the time. We are now in the afternoon. I hope everyone's enjoying day one of our healthcare conference. My name is Akash Tewari. I'm a pharma and biotech analyst here. I have the pleasure of hosting the Madrigal management team today.
I will -- before we get into Q&A on my end, I will hand it off to Paul and team to give some brief introductions and then we'll take it from there.
Thank you, Akash. We are Madrigal Pharmaceuticals. We have completed several Phase 3 studies with successful outcomes in nonalcoholic steatohepatitis and we are working diligently to file our NDA under Subpart H looking for accelerated approval. And we've guided to the end of this month to have filed the NDA. That's where we are, and we are anxious to get our document in.
Questions & Answers
Understood. So maybe let's start off with some of the remaining card
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)